Imperial College London
Portrait Picture

Dr Mark P. Lythgoe

Faculty of Medicine, Department of Surgery & Cancer

Research Postgraduate
 
 
 
//

Contact

 

m.lythgoe

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Blagden:2023:10.1038/s41416-022-02051-7,
author = {Blagden, SP and Yu, L-M and Ellis, S and Hughes, H and Shaaban, A and Fennelly-Barnwell, J and Lythgoe, MP and Cooper, AM and Maignen, FM and Buckland, SW and Kearns, PR and Brown, LC and Experimental, Cancer Medicine Centres ECMC CID trials working group},
doi = {10.1038/s41416-022-02051-7},
journal = {British Journal of Cancer},
pages = {474--477},
title = {Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective},
url = {http://dx.doi.org/10.1038/s41416-022-02051-7},
volume = {128},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In our 2020 consensus paper, we devised ten recommendations for conducting Complex Innovative Design (CID) trials to evaluate cancer drugs. Within weeks of its publication, the UK was hit by the first wave of the SARS-CoV-2 pandemic. Large CID trials were prioritised to compare the efficacy of new and repurposed COVID-19 treatments and inform regulatory decisions. The unusual circumstances of the pandemic meant studies such as RECOVERY were opened almost immediately and recruited record numbers of participants. However, trial teams were required to make concessions and adaptations to these studies to ensure recruitment was rapid and broad. As these are relevant to cancer trials that enrol patients with similar risk factors, we have added three new recommendations to our original ten: employing pragmatism such as using focused information sheets and collection of only the most relevant data; minimising negative environmental impacts with paperless systems; and using direct-to-patient communication methods to improve uptake. These recommendations can be applied to all oncology CID trials to improve their inclusivity, uptake and efficiency. Above all, the success of CID studies during the COVID-19 pandemic underscores their efficacy as tools for rapid treatment evaluation.
AU  - Blagden,SP
AU  - Yu,L-M
AU  - Ellis,S
AU  - Hughes,H
AU  - Shaaban,A
AU  - Fennelly-Barnwell,J
AU  - Lythgoe,MP
AU  - Cooper,AM
AU  - Maignen,FM
AU  - Buckland,SW
AU  - Kearns,PR
AU  - Brown,LC
AU  - Experimental,Cancer Medicine Centres ECMC CID trials working group
DO  - 10.1038/s41416-022-02051-7
EP  - 477
PY  - 2023///
SN  - 0007-0920
SP  - 474
TI  - Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
T2  - British Journal of Cancer
UR  - http://dx.doi.org/10.1038/s41416-022-02051-7
UR  - http://hdl.handle.net/10044/1/100803
VL  - 128
ER  -
Download